On 5^th Dec, 2023, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Ketoprofen (Y20220000371) API from NMPA.

 Clinical studies have shown that ketoprofen, as an important non-steroidal anti-inflammatory drug, has significant advantages such as small dose, high efficacy, good tolerance and mild side effects compared with similar drugs. At present, the domestic market ketoprofen preparation products mainly include cataplasms, enteric capsule, sustained release capsule, sustained release tablet, gel, liniment, suppositories and patches and other dosage forms. It is worth mentioning that in March 2023, Jiudian Pharmaceutical's ketoprofen cataplasms was officially approved for sale, which is the first imitation and exclusive dosage form in China.

According to professional analysis, the market size of musculoskeletal system drugs is stable and is expected to continue to grow in the future. The successful conversion of ketoprofen API to "A" is a concentrated reflection of Jiudian's adherence to the integrated development strategy of pharmaceutical preparations, APIs and excipients, which is conducive to the company's market development in the field of musculoskeletal system drugs and improves the company's market competitiveness in this treatment field.